A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects.

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2010

At a glance

  • Drugs Digoxin; Latrepirdine
  • Indications Alzheimer's disease; Atrial fibrillation; Heart failure; Huntington's disease
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Mar 2010 Results have been presented at the 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Additional location identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top